NICE rejects Adcetris (brentuximab vedotin) as a treatment for relapsed or refractory Hodgkin lymphoma . -Takeda.
Adcetris (brentuximab vedotin) from Takeda is now being reviewed by the National Institute for Health and Care Excellence (NICE) for relapsed or refractory Hodgkin lymphoma and also for the treatment of patients with CD30+ HL at increased risk of relapse or progression following autologous stem cell transplant (ASCT). NICE has reached the conclusion that evidence around the drug's clinical effectiveness is "immature and limited", and that it could not be considered a cost effective use of NHS resources. According to Takeda, this decision should be made final within the Final Appraisal Determination expected in January 2017.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.